
Debt Financing ·
Positron issues three promissory notes at 20% interest, with warrants
The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share.
POSC POSITRON CORP

Debt Financing ·
The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share.
The note matures on August 13, 2028 and bears fixed interest at 12%. Cash is payable only on demand after maturity or while an event of default continues.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $461,452 | $587,500 |
| Net income (loss) | -$10.6 million | -$2.4 million |
| Cash from operations | -$4.7 million | -$1.7 million |
POSITRON CORP trades under the ticker POSC on OTC.
POSITRON CORP is listed on OTC.
Our directory records POSITRON CORP under United States.
aibio.space lists POSITRON CORP among 2,820 public biotech companies and publishes its news here as stories appear.
$461,452 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
POSITRON CORP reported a net loss of $10.6 million for the fiscal year ended Dec 31, 2025, and used $4.7 million of cash in operations, per its annual report to the SEC.
$28,000 in cash at Sep 30, 2015, per its 10-Q.
Our latest story on POSITRON CORP, dated Sep 30, 2026: "Positron issues three promissory notes at 20% interest, with warrants". The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share. Source.
Our latest debt story, dated Sep 30, 2026: "Positron issues three promissory notes at 20% interest, with warrants". The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share. Source.
Press Follow on this page to add POSITRON CORP to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming POSITRON CORP so far, in Debt Financing.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction